AVTX (Avalo Therapeutics) Moat Score: 3/10 (As of Jun. 28, 2026)


AVTX Avalo Therapeutics Inc AVTX
23 GF Score
Price $18.16
GF Value $0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Avalo Therapeutics Moat Score?

Avalo Therapeutics AVTX +1.11% 23 Moat Score is 3 as of Jun. 28, 2026. GuruFocus rates AVTX with a GF Score™ of 23/100 and a GF Value™ of $0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,402 Biotechnology companies, Avalo Therapeutics ranks better than 75.46% on this metric.

Avalo Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Avalo Therapeutics has No Moat: Avalo Therapeutics has some intellectual property in drug development, but lacks market leadership, strong brand strength, and regulatory barriers, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Avalo Therapeutics might have No Moat - Very weak/transient advantages.

Avalo Therapeutics  (NAS:AVTX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Avalo Therapeutics Moat Score Related Terms

AVTX vs EVMN, TBPH, VOR: Moat Score Comparison

For the Biotechnology subindustry, Avalo Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avalo Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's Moat Score falls into.


AVTX
23GF Score
Avalo Therapeutics Inc AVTX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Avalo Therapeutics (AVTX) has a Moat Score of 3 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Avalo Therapeutics ranks #344 out of 1402 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Avalo Therapeutics' Moat Score too high?
Avalo Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Avalo Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Avalo Therapeutics ranks #344 out of 1402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avalo Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' Moat Score compare to EVMN and TBPH?
According to the Biotechnology industry distribution chart, Avalo Therapeutics ranks #344 out of 1402 companies for Moat Score. This places Avalo Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Avalo Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avalo Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avalo Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (AVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $18.16 — trading 60433.3% above its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Avalo Therapeutics' overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Avalo Therapeutics (AVTX), the current Moat Score is 3 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avalo Therapeutics (AVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of $18.16 is trading 60433.3% above its estimated GF Value™ of $0.03. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for AVTX:

  • Moat Score: 3
  • GF Value™: $0.03 vs. price of $18.16 (60433.3% above fair value)
  • GF Score™: 23/100 with 5 warning signs
  • Industry Position: 50% above the Biotechnology median (#344 of 1402)

No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avalo Therapeutics Business Description

Other Exchanges C6K0:Germany
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
23GF Score

Get the complete analysis for AVTX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.16
Price
$0.03
GF Value